ASAQ registered in 35 countries & territories
More than 516 million treatments distributed
In October 2008, the WHO granted ASAQ a “pre-qualified” status.
Registration applications were submitted in 30 malaria-endemic African countries and approval were obtained in 28 of them between November 2006 and September 2010. ASAQ was also registered in India in 2010.
Field Monitoring Programme
DNDi, Sanofi and additional partners, in particular MMV and National Malaria Control Programmes, are implementing a comprehensive “ASAQ Field Monitoring Programme” that aims to collect high-quality data on ASAQ effectiveness and safety profile in “the field”. This programme includes a series of proactive clinical studies conducted in several countries of sub-Saharan Africa with different levels of disease transmission.
Key ongoing studies include two post-registration studies being done in collaboration with MSF, Epicentre, and the National Malaria Control Programme in Liberia. In Ivory Coast, two clinical studies are being set up in collaboration between Sanofi, MMV, and DNDi. Ultimately, more than 20,000 patients will be followed as part of this monitoring plan.
Market and policy surveys
* ASAQ produced by Sanofi only. Statistics on generic ASAQ available from WHO after one year.
|ASAQ is registered in:|
Central African Republic
Tanzania (+ Zanzibar)